We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
Cap. Flow
+$154M
Cap. Flow %
10.62%
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.6 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.6 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.9 years

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$37.6M
2
CYH icon
Community Health Systems
CYH
+$28.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$27.8M
4
CTLT icon
CATALENT, INC.
CTLT
+$23M
5
MASI icon
Masimo
MASI
+$18.2M

Top Sells

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$26.7M
2
AMRN icon
Amarin Corp
AMRN
+$24.9M
3
OGN icon
Organon & Co
OGN
+$21.2M
4
DHR icon
Danaher
DHR
+$17.4M
5
AMN icon
AMN Healthcare
AMN
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.74%
2 Miscellaneous 17.65%
3 Industrials 1.16%
4 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GOCO icon
51
DELISTED
GoHealth
GOCO
$6.35M 0.44%
84,115
+79,522
+1,731% +$8.42M
2020 Q3
4 quarters
HRC
52
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$4.5M 0.31%
+30,000
New +$4.05M
2021 Q3
0 quarters
HRC
53
CALL
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$4.41M 0.31%
+29,400
New +$3.97M
2021 Q3
0 quarters
LXRX icon
54
Lexicon Pharmaceuticals
LXRX
$676M
$4.2M 0.29%
872,694
+643,405
+281% +$2.64M
2021 Q1
2 quarters
APLS icon
55
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$4.17M 0.29%
+126,400
New +$7.1M
2021 Q3
0 quarters
ARKK icon
56
ARK Innovation ETF
ARKK
$8.47B
$3.87M 0.27%
35,000
-50,000
-59% -$6.02M
2021 Q1
2 quarters
SRGA
57
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$3.82M 0.26%
116,951
-12,452
-10% -$456K
2021 Q1
2 quarters
EDIT icon
58
CALL
Editas Medicine
EDIT
$361M
$3.7M 0.26%
+90,000
New +$4.93M
2021 Q3
0 quarters
MRK icon
59
CALL
Merck
MRK
$360B
$3.66M 0.25%
48,700
– –
2021 Q2
1 quarter
DXCM icon
60
DexCom
DXCM
$32.4B
$3.5M 0.24%
25,604
-12,496
-33% -$1.58M
2020 Q4
3 quarters
SIBN icon
61
SI-BONE Inc
SIBN
$882M
$3.21M 0.22%
+150,000
New +$3.8M
2021 Q3
0 quarters
ISRG icon
62
Intuitive Surgical
ISRG
$150B
$3.13M 0.22%
9,435
+1,686
+22% +$566K
2021 Q1
2 quarters
EVH icon
63
Evolent Health
EVH
$520M
$3.11M 0.21%
+100,170
New +$2.4M
2021 Q3
0 quarters
KRTX icon
64
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.06M 0.21%
+25,000
New +$2.89M
2021 Q3
0 quarters
A icon
65
Agilent Technologies
A
$48.8B
$2.94M 0.2%
18,660
+3,399
+22% +$550K
2020 Q4
3 quarters
PBYI icon
66
Puma Biotechnology
PBYI
$509M
$2.79M 0.19%
+397,940
New +$2.98M
2021 Q3
0 quarters
VRDN icon
67
Viridian Therapeutics
VRDN
$2.17B
$2.63M 0.18%
+160,000
New +$2.35M
2021 Q3
0 quarters
AUTL icon
68
Autolus Therapeutics
AUTL
$426M
$2.61M 0.18%
398,074
-75,000
-16% -$474K
2021 Q2
1 quarter
LQDA icon
69
Liquidia Corp
LQDA
$3.05B
$2.56M 0.18%
929,049
-50,000
-5% -$130K
2021 Q1
2 quarters
MORF icon
70
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.47M 0.17%
+43,600
New +$2.64M
2021 Q3
0 quarters
OM icon
71
Outset Medical
OM
$74.1M
$2.35M 0.16%
3,167
-3,986
-56% -$2.72M
2021 Q2
1 quarter
ADAP
72
DELISTED
Adaptimmune Therapeutics
ADAP
$2.3M 0.16%
+444,887
New +$2M
2021 Q3
0 quarters
HSTM icon
73
HealthStream
HSTM
$1.02B
$2.22M 0.15%
77,812
– –
2021 Q2
1 quarter
MREO icon
74
Mereo BioPharma
MREO
$49.1M
$2.18M 0.15%
+899,569
New +$2.38M
2021 Q3
0 quarters
ANAB icon
75
AnaptysBio
ANAB
$1.39B
$2.12M 0.15%
+78,054
New +$1.98M
2021 Q3
0 quarters
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.

  • Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
  • Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
  • Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
  • Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
  • Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
  • Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
  • Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.